Skip to content
OpenCapital
Get started

Prestige Consumer Healthcare PBH Accrued production costs

Other financials

Income statement

See full
Revenue$281.6M-5.0%
Gross profit$146.3M-13.9%
Operating income$75.5M-14.6%
Net income$53.9M+7.6%
EPS (diluted)$1.13+11.9%

Balance sheet

See full
Cash & equivalents$63.9M-34.8%
Total debt$1.0B-0.2%
Total equity$1.9B+2.9%
Total assets$3.5B+2.7%

Cash flow

See full
Operating cash flow$42.8M-30.7%
CapEx$5.2M+49.8%
Free cash flow$37.6M-35.5%

Valuation

See full
Market cap$2.24B-34.1%

Profitability

See full
Gross margin54.7%-1.1pp
Operating margin28.4%-1.2pp
Net margin17.5%-1.4pp
FCF margin22.6%+1.3pp

Returns & leverage

See full
Return on equity10.2%-2.1pp
Debt / equity0.6×0.0×
Current ratio3.6×-0.6×

Where this comes from

Reported directly by Prestige Consumer Healthcare in its filing.

Tagged under the XBRL concept pbh:AccruedProductionCostsCurrent.

The official record: Prestige Consumer Healthcare’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Prestige Consumer Healthcare's accrued production costs?
Prestige Consumer Healthcare (PBH) reported accrued production costs of $6.64M in Q4 2025.
How has Prestige Consumer Healthcare's accrued production costs changed year-over-year?
Prestige Consumer Healthcare's accrued production costs decreased by 1.0% year-over-year, from $6.71M to $6.64M.
What is the long-term trend for Prestige Consumer Healthcare's accrued production costs?
Over 4 years (2021 to 2025), Prestige Consumer Healthcare's accrued production costs has grown at a 22.1% compound annual growth rate (CAGR), from $2.88M to $6.42M.